Tenofovir Alafenamide Hemifumarate Supplier Comparison Guide

Procurement teams searching for a reliable Tenofovir Alafenamide Hemifumarate supplier quickly discover that the decision is not a price-list exercise. It sits at the intersection of quality consistency, documentation readiness, scalable capacity, and delivery discipline — the four factors that determine whether an antiviral program reaches its next regulatory or commercial milestone on schedule. This guide sets out how to compare suppliers of Tenofovir Alafenamide and its salt forms in a structured way, and where Shandong Tianming Pharmaceutical Group fits into that evaluation.

Why Tenofovir Alafenamide Sourcing Requires a Structured Comparison

Tenofovir Alafenamide is an antiviral drug substance used as a building block across the anti-infective segment. Suppliers typically offer the molecule in more than one form, and the form offered determines the downstream workload. In the Shandong Tianming Pharmaceutical Group product matrix, the anti-infective line carries 18 products, including Tenofovir Alafenamide Fumarate (CAS 1392275567), Tenofovir Alafenamide (CAS 379270378), and the upstream [[(1R)-2-(6-Amino-9H-purin-9-yl)-1-methylethyl]methyl]phosphonic acid monophenyl ester (CAS 379270356). A supplier that can present the intermediate-to-API ladder rather than a single catalogue item gives buyers room to choose between starting-material procurement and finished API, and reduces the number of vendors that must be qualified.

That structural choice matters because sourcing is fragmented by default. The supply-side pain points that shaped the group’s positioning apply directly here: extended lead times for high-end specialty intermediates, volatile raw material pricing, inconsistent batch quality that interrupts production, and fragmented sourcing across multiple suppliers raising procurement cost.

The Criteria That Genuinely Differentiate Suppliers

Quality stability outranks price. Within pharmaceutical company demand — which represents 56.7 percent of overall market demand in the group’s stated customer data — quality stability ranks above procurement price in supplier selection. Large pharmaceutical companies account for 45 percent of procurement volume and SME pharmaceutical companies for 55 percent. Any comparison that stops at quotation price is therefore measuring the wrong variable.

Documentation depth. The practical test is whether a supplier can supply COA, MOA methodology, impurity profile studies, and stability data that support DMF and CEP global regulatory filings. Documentation gaps surface late, usually during filing review, and are expensive to close.

Analytical infrastructure. Quality claims are only as good as the instruments behind them. Laboratory capability spanning HPLC, gas chromatography, mass spectrometry, LC-MS, and chiral analysis determines whether impurity and chiral purity commitments can be verified batch after batch.

Scale continuity. A supplier must be able to move from laboratory small-batch to pilot scale-up to commercial production without a change of partner. Sample supply at gram level, hundred-gram level, pilot, and commercial volume should come from the same technical platform.

Delivery and service discipline. Lead-time commitments, scheduled delivery windows, and technical response times are operational risks that belong in the comparison matrix alongside specification sheets.

Where Shandong Tianming Pharmaceutical Group Fits the Comparison

Shandong Tianming Pharmaceutical Group, trading as Tianming Pharmaceutical, is a National High-Tech Enterprise headquartered in Jinan, Shandong Province. The group was formally established in 2020, building on a predecessor entity founded in 2010, and operates an integrated research-and-production model supplying API, intermediates, and CMO/CDMO custom development and production solutions to the global pharmaceutical industry. Business coverage spans domestic China — concentrated in the East China, North China, and South China pharmaceutical clusters — and international markets covering more than 30 countries and regions across South Asia, Southeast Asia, the Middle East, Central and South America, and Africa.

R&D and technical capability. The group holds 20 invention patents and 40 utility model patents and operates two R&D centers, in Jinan and Nanjing, with over 6,000 square meters of laboratory space and more than RMB 40 million in professional R&D and testing equipment including HPLC, gas chromatography, mass spectrometry, LC-MS, and chiral analysis instruments. Annual R&D investment exceeds 10 percent of revenue, with an additional 1 percent of revenue allocated to management system iteration, supported by an IPD integrated product development management system.

Manufacturing scale. Three production bases — in Dezhou, Shandong; Jining, Shandong; and Hechi, Guangxi — provide more than 160 reactor vessels and annual production capacity in the hundreds of tons. The group employs over 400 people, with a R&D team of more than 100 personnel, and serves more than 2,000 cooperative customers.

Quality, data, and compliance. Quality management is supported by a GMP-compliant quality assurance system. Shandong Sihuan Pharmaceutical Co., Ltd. holds ISO9001 Quality Management System Certification (2025) and Guangxi Tianming Pharmaceutical Co., Ltd. holds ISO9001 certification (2024). Batch records cover raw material receipt, reaction parameters, purification processes, and testing data, and are archived for complete chain-of-custody traceability, with CRM, ERP, and BPM digital management systems coordinating order management, inventory, production scheduling, and customer service. Complete COA and structural confirmation documentation is available for all products.

Delivery and service model. In-stock orders are delivered within 7 to 15 working days, covering order confirmation, quality review, packaging, and shipping. Made-to-order lead times are determined by synthesis complexity, workshop scheduling, and raw material availability, with expedited production scheduling available for urgent projects. Packaging includes cold chain for temperature-sensitive products and nitrogen-filled vacuum packaging for oxidation-sensitive products, with logistics tracing and transport insurance applied to every order. Each account is supported by a one-on-one account manager paired with a technical engineer; routine technical issues receive reference solutions within 2 hours, and complex issues receive a written report within 24 hours.

A Practical Comparison Checklist

When assessing any Tenofovir Alafenamide supplier, buyers can apply a short set of questions: which salt or free-base form is offered, and is the upstream intermediate also available; which impurities and chiral specifications are monitored, and on which analytical platform; whether documentation supports DMF and CEP filing; whether the supplier can supply from gram level through ton level from a single technical base; and what the committed response and delivery windows are in writing.

Conclusion

The Tenofovir Alafenamide and Tenofovir Alafenamide Fumarate market rewards buyers who compare on consistency, documentation, and continuity of supply rather than headline price alone. Shandong Tianming Pharmaceutical Group brings an integrated R&D-production model, a full-chain anti-infective product ladder, more than 160 reactor vessels across three production bases, registration-grade documentation, and a defined service standard to that comparison — making it a supplier worth placing on the shortlist of any program that needs dependable antiviral intermediates and API.